The short answer: Between 40% and 60% of women develop clinically significant insomnia during the menopause transition. The first-line treatment is cognitive behavioural therapy for insomnia (CBT-I), which outperforms sleep medication at six and twelve months in menopausal populations. Where night sweats fragment sleep, treating the vasomotor symptoms — with estradiol, fezolinetant, or an SNRI — restores sleep continuity. Bedtime micronized progesterone helps many women. Screen for obstructive sleep apnoea and restless legs before accepting a hypnotic: apnoea prevalence roughly triples after menopause and is routinely missed in women.
Sleep is the symptom women most often describe as the one that broke them. It compounds everything else: mood, cognition, appetite regulation, glucose control, and pain tolerance all degrade with fragmented sleep. Menopausal insomnia also has a specific, treatable structure — it is rarely just "getting older" — and it responds to a sequenced plan far better than to a prescription for zolpidem.
Menopause sleep quiz
Eight questions modelled on the Insomnia Severity Index and the sleep measures used in menopause trials. You get a 0–100 score, a band, and the guideline-concordant next step. No email required.
Treatment comparison table
10 options, with the effect reported in trials, how fast it arrives, the evidence grade, and an honest verdict — including the ones that do not work.
| Treatment | Class | Effect | First benefit | Evidence | Side effects | Verdict |
|---|---|---|---|---|---|---|
| CBT for insomnia (CBT-I) | Behavioral | Largest durable improvement; effects hold at 12 months | 2–4 wksfull effect ~8 wks | A — multiple RCTsMsFLASH 03: telephone CBT-I reduced Insomnia Severity Index scores substantially more than menopause education control. | Temporary sleepiness during sleep restriction. | First-line in every guideline. Effective even when hot flashes persist. |
| Estradiol (when night sweats fragment sleep) | Hormonal | Restores sleep continuity by removing the arousal trigger | 1–3 wksfull effect ~12 wks | A — multiple RCTsMsFLASH 01 and pooled analyses: low-dose oral estradiol improved insomnia symptoms versus placebo. | Breast tenderness, spotting, headache. Progestogen required with a uterus. | The right choice when the waking event is a night sweat. |
| Micronized progesterone 200–300 mg at bedtime | Hormonal | Improved sleep quality and reduced wake after sleep onset | 1–2 wksfull effect ~8 wks | B — RCT or strong cohortCaufriez and Prior trials: micronized progesterone improved slow-wave sleep and sleep efficiency in postmenopausal women. | Morning grogginess if dosed too late, dizziness, breast tenderness. | Strong practical option — you may need it for endometrial protection anyway. |
| Fezolinetant (Veozah) | Non-hormonal prescription | Improves sleep disturbance scores by reducing nocturnal vasomotor events | 1–2 wksfull effect ~12 wks | A — multiple RCTsSKYLIGHT 1 and 2 included validated sleep-disturbance secondary endpoints, both improved versus placebo. | Abdominal pain, insomnia in a minority, hepatic transaminase monitoring required. | Hormone-free route to the same mechanism when the driver is night sweats. |
| Gabapentin at bedtime | Non-hormonal prescription | Reduces nocturnal flashes and increases slow-wave sleep | 1–2 wksfull effect ~8 wks | B — RCT or strong cohortRandomized trials in menopausal women show reduced night-time vasomotor events and improved sleep quality. | Dizziness, next-day grogginess, unsteadiness. | Useful for night-dominant symptoms, particularly with restless legs. |
| Treating obstructive sleep apnoea | Root-cause | Transformative where apnoea is present | 1–4 wksfull effect ~12 wks | A — multiple RCTsEstablished sleep-medicine evidence; post-menopausal prevalence rises roughly threefold and is under-diagnosed in women. | Mask tolerance issues. | Screen before you sedate. A missed apnoea diagnosis wastes years. |
| Iron repletion for restless legs | Correctable deficiency | Resolves symptoms where ferritin is below 75 ng/mL | 4–8 wksfull effect ~16 wks | B — RCT or strong cohortRestless legs guidelines recommend iron repletion targeting ferritin above 75 ng/mL. | Constipation, nausea. | Common in perimenopause because of heavy bleeding. Easy to check. |
| Melatonin | Supplement | Small effect on sleep onset only; no meaningful effect on maintenance | 1–2 wksfull effect ~4 wks | C — limited or mixedMeta-analyses show a modest reduction in sleep-onset latency; menopausal maintenance insomnia is largely unaffected. | Vivid dreams, morning grogginess at high doses. | Low-dose melatonin is reasonable for circadian timing, not for 3 a.m. waking. |
| Z-drugs and benzodiazepines | Sedative | Short-term sleep gain, poor durability | 0–1 wksfull effect ~2 wks | C — limited or mixedEffective acutely; guidelines restrict to short-term use because of tolerance, falls, and memory impairment. | Memory impairment, falls, next-day sedation, dependence. | Situational only. Kindr does not prescribe open-ended hypnotics. |
| Alcohol as a sleep aid | Supplement | Worsens sleep — faster onset, fragmented second half | 0 wkfull effect ~0 wks | D — no reliable benefitAlcohol suppresses REM, causes rebound arousal, and increases nocturnal vasomotor events. | Dependence risk, worsened flashes, weight gain. | The most common self-treatment and the most counterproductive. |
When each treatment starts working
The most common reason a treatment "fails" is stopping before it has had time to work. The bar shows the window in which trials report first noticeable benefit; the marker shows full effect.
- Z-drugs and benzodiazepinesfirst benefit wks 0–1 · full ~wk 2
- Micronized progesterone 200–300 mg at bedtimefirst benefit wks 1–2 · full ~wk 8
- Gabapentin at bedtimefirst benefit wks 1–2 · full ~wk 8
- Estradiol (when night sweats fragment sleep)first benefit wks 1–3 · full ~wk 12
- Fezolinetant (Veozah)first benefit wks 1–2 · full ~wk 12
- Treating obstructive sleep apnoeafirst benefit wks 1–4 · full ~wk 12
- CBT for insomnia (CBT-I)first benefit wks 2–4 · full ~wk 8
- Iron repletion for restless legsfirst benefit wks 4–8 · full ~wk 16
Why sleep breaks in menopause
Three mechanisms stack. First, vasomotor events: a nocturnal hot flash triggers a cortical arousal roughly a minute before the subjective flush, fragmenting sleep even when you do not fully wake. Second, the loss of progesterone, whose metabolite allopregnanolone is a positive allosteric modulator at GABA-A receptors — effectively the body's own sedative. Third, circadian and thermoregulatory drift: core temperature regulation narrows exactly when the overnight temperature nadir should be deepest.
Layered on top are the acquired factors: rising obstructive sleep apnoea risk, restless legs from perimenopausal iron loss, anxiety, alcohol used as a sleep aid, and conditioned arousal — the learned association between bed and frustration that keeps insomnia going long after the original trigger has resolved.
That last mechanism is why insomnia often persists after hot flashes settle, and why the highest-value treatment is behavioural rather than pharmacological.
Choosing a treatment
If your sleep breaks because of night sweats, treat the night sweats — sleep follows. If your sleep is broken without vasomotor symptoms, CBT-I is the first-line treatment in every major guideline, with durable effects that hypnotics do not produce.
Micronized progesterone at bedtime is a genuinely useful option for women who need endometrial protection anyway, and it is the only hormone with a plausible direct sedative mechanism.
Hypnotics have a narrow role: short-term, situational, and never as the only intervention. Z-drugs impair memory consolidation and increase fall risk, and tolerance builds quickly.
- Screen for sleep apnoea and restless legs before prescribing anything sedating.
- CBT-I first for chronic insomnia without a vasomotor driver.
- Treat night sweats when they are the fragmenting event.
- Bedtime micronized progesterone when hormone therapy is otherwise appropriate.
- Alcohol is a sleep destroyer that feels like a sleep aid — it suppresses REM and worsens nocturnal flashes.
When to escalate
- Witnessed breathing pauses, gasping, or loud snoring — refer for a sleep study.
- Unrefreshing sleep despite seven or more hours in bed.
- Irresistible urge to move the legs at night with an evening crescendo — check ferritin, target above 75 ng/mL.
- Acting out dreams or violent movement in sleep — needs neurological assessment.
- Early-morning waking with pervasive low mood and loss of interest — treat the depression, not just the sleep.
Kindr Health Menopause Sleep Evidence Synthesis (2026)
Structured synthesis of the randomized trials and cohorts underpinning behavioral, hormonal, non-hormonal prescription, and sedative treatment of menopausal insomnia. Free to cite with attribution (CC BY 4.0).
| Trial | Year | n | Intervention | Comparator | Endpoint | Result |
|---|---|---|---|---|---|---|
| MsFLASH 03McCurry SM et al. JAMA Intern Med 2016 | 2016 | 106 | Telephone-delivered CBT-I | Menopause education control | Insomnia Severity Index | Large, durable reduction in insomnia severity |
| MsFLASH 01Ensrud KE et al. Sleep 2015 | 2014 | 339 | Low-dose oral estradiol or venlafaxine | Placebo | Insomnia and sleep quality | Both improved insomnia symptoms versus placebo |
| Caufriez progesterone sleep studyCaufriez A et al. J Clin Endocrinol Metab 2011 | 2011 | 8 | Micronized progesterone 300 mg | Placebo | Polysomnographic sleep architecture | Restored slow-wave sleep without next-day impairment |
| SKYLIGHT 2 sleep endpointJohnson KA et al. Obstet Gynecol 2023 | 2023 | 484 | Fezolinetant 30 or 45 mg | Placebo | PROMIS Sleep Disturbance | Significant improvement versus placebo |
| SWAN Sleep StudyKravitz HM et al. Menopause 2008 | 2008 | 3,045 | Longitudinal cohort | Premenopausal baseline | Self-reported sleep difficulty | Difficulty rose from 32% premenopause to 40–60% in late transition |
| Menopause and OSA cohortYoung T et al. Am J Respir Crit Care Med 2003 | 2003 | 589 | Polysomnography by menopausal status | Premenopausal women | Apnoea-hypopnoea index | Substantially higher odds of sleep-disordered breathing after menopause |
The Kindr Menopause Sleep Index
Live aggregate of anonymous sleep quiz submissions: mean severity score, median night wakings, disrupted nights per week, share reporting significant daytime impact, and share on no treatment.
The index publishes once at least 10 anonymous submissions are in (currently 0). Take the quiz above to contribute.
Self-reported, de-identified, aggregate-only. Journalists and researchers may cite with attribution to The Kindr Menopause Sleep Index.
Sleeping badly and tired of being handed a hygiene leaflet? A Kindr clinician will screen for apnoea, treat the driver, and set up CBT-I.
Start your visit →Not ready? Ask Dot, our free AI menopause companion.
Frequently asked questions
Why do I wake at 3 a.m. every night?
The second half of the night is REM-dense and coincides with the core temperature nadir, so it is when nocturnal vasomotor events and cortisol rise intersect. Alcohol earlier in the evening worsens this specific pattern by causing rebound arousal as it clears.
Is CBT-I really better than a sleeping pill?
For chronic insomnia, yes. Hypnotics work faster but lose effect and carry falls and memory risk; CBT-I takes four to eight weeks and the benefit persists at twelve months and beyond. That is why every major guideline lists it first.
Does HRT fix menopause insomnia?
It reliably helps when night sweats are the fragmenting event. If your sleep is broken without vasomotor symptoms, hormone therapy is a weaker choice than CBT-I, though bedtime micronized progesterone helps many women directly.
Should I take melatonin?
Low-dose melatonin helps shift sleep timing and reduce onset latency modestly. It does not fix the middle-of-the-night waking that characterises menopausal insomnia.
Could this be sleep apnoea?
Quite possibly. Risk rises sharply after menopause and women present atypically, with insomnia and fatigue rather than loud snoring. Unrefreshing sleep, morning headache, or witnessed pauses should trigger a sleep study.
How long does menopause insomnia last?
Untreated it often outlives the hot flashes because conditioned arousal keeps it going. Treated properly — driver removed plus CBT-I — most women see meaningful change within eight weeks.
The menopause sleep hub
Mechanism, CBT-I, night sweats, apnoea, treatment comparison, and what sleep hygiene misses.
Other Kindr symptom hubs
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- Sleep & menopauseJournal
- Is HRT safe?Journal
- DSIP — delta sleep peptidePeptide
- When to start HRTJournal
- Epitalon — circadian repairPeptide
- Menopause HRT serviceMedication
Sources
- McCurry SM et al. Telephone-based CBT for insomnia in perimenopausal and postmenopausal women (MsFLASH 03). JAMA Intern Med 2016.
- Ensrud KE et al. Effects of estradiol and venlafaxine on insomnia symptoms (MsFLASH). Sleep 2015.
- Caufriez A et al. Progesterone prevents sleep disturbances in postmenopausal women. J Clin Endocrinol Metab 2011.
- Kravitz HM et al. Sleep difficulty in women at midlife (SWAN). Menopause 2008.
- Young T et al. Menopausal status and sleep-disordered breathing. Am J Respir Crit Care Med 2003.
- The Menopause Society. 2023 Nonhormone Therapy Position Statement.
- American Academy of Sleep Medicine. Clinical Practice Guideline for Behavioral Treatment of Chronic Insomnia.
Educational content only — not a substitute for professional medical advice, diagnosis, or treatment. The severity quiz is a screening aid, not a diagnosis. Reviewed by the Kindr Health clinical team · Last reviewed 2026-07-26.